Title
Category
Credits
Event date
Cost
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
The potential consequences of medical misinformation on public health, such as the spread of vaccine hesitancy, will be discussed, and participants will come away empowered with additional strategies and tools to more effectively address medical misinformation and promote accurate health information to patients and the wider community.
  • Disease management
  • Health equity
  • 1.00 AAFP - Family Physicians
  • 1.00 ABIM MOC - Physicians
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
Pulmonary function tests (PFTs) are commonly utilized for the diagnosis and ongoing monitoring of pulmonary conditions. However, the inclusion of race in the reporting and interpretation of PFT results introduces the potential to contribute to health disparities and amplify race-based health inequities. This activity aims to enhance participants’ comprehension of race-based adjustments in clinical algorithms and increase competency in race-neutral and impartial interpretation of PFTs. The faculty speaker for this webcast, Dr. Nirav Bhakta, served as the co-chair of the American Thoracic Society (ATS) workshop responsible for shaping the 2023 ATS statement on race in PFT interpretation. Drawing upon his extensive expertise as a pulmonologist and his pivotal role in the formulation of these new ATS guidelines, Dr. Bhakta will delve into the historical context behind race-specific PFTs, address the rationale behind the shift and review the pivotal aspects and implications of adopting a race-neutral approach.
  • Disease management
  • Rare diseases
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 CDR - Dietitians
  • 1.25 ASWB - Social Workers
$0.00
Millions of people around the world suffer from rare and undiagnosed diseases, often leading to years of frustration, uncertainty, and distress. This session will explore the latest approaches and tools for diagnosing and managing rare diseases. It will delve into cutting-edge genetic-sequencing technologies and advanced data analytics that can assist and guide diagnosis. Participants will also learn about interdisciplinary teams and patient advocacy and the impact they have on solving these complex medical problems.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will outline the current state of diabetes therapy and review recent data regarding the effectiveness of remission-related approaches. It will also discuss available and emerging AI applications that can assist patients with glycemic control.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Chronic kidney disease (CKD), typically caused by diabetes and hypertension, affects 15% of US adults and continues to increase with the rising prevalence of these conditions. Increased health care utilization and high morbidity/mortality rates are associated with the progression of CKD to kidney failure with comorbid cardiovascular disease, anemia and bone disease. This session will examine the current state of care for CKD, including recent advancements and interventions that can slow CKD progression and preserve kidney function and strategies to optimize care pathways for managing CKD and its common comorbidities.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will focus on enhancing our understanding of the current opioid crisis and will explore new angles and address current concerns, including the use of over-the-counter intranasal naloxone, the evolving landscape of opioids with a focus on fentanyl, the intersection between suicide and opioid overdoses, the significance of the new 988 helpline in the crisis, and the viability of home-based detox startups. Strategies to effectively address the ongoing challenges of the opioid crisis will be discussed.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity aims to explore best practices in cancer screening and shed light on the groundbreaking WISDOM Study, which is revolutionizing our approach to screening by testing a personalized precision-medicine method based on individual risk factors for breast cancer in contrast to traditional annual mammograms. Participants will learn how this alternative approach differs from the current “one-size-fits-all” guideline-based method and discuss its potential to significantly improve the effectiveness of screening.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Alzheimer’s disease (AD) is a pressing public health crisis, affecting more than 6 million people in the U.S. and increasing in prevalence with the aging population. Join us in exploring the latest advances in AD diagnosis and management, including biomarkers, imaging techniques and cognitive assessments. Emerging pharmacological therapies that target the underlying disease and novel approaches to optimizing patient care will be highlighted.
  • Behavioral health
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
Identification and early intervention for pregnant and postpartum women with substance-use disorders (SUD) are critical for optimizing maternal and neonatal health and wellbeing. The risk factors, common barriers to treatment, evidence-based practices around screening and interventions, and the framework for collaborative strategies to support pregnant and postpartum women with SUD will be discussed.
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.

Pages